Skip to content Skip to footer
Subscribe Now
PharmaShots' Key Highlights of Second Quarter 2022
INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2022

The second quarter of 2022 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) meet its primary endpoints for heart failure with a preserved ejection fractionStarting with the latest acquisitions, Pfizer acquire Biohaven for ~$11.6B, GSK acquire Affinivax for ~$3.3B. The second quarter of the year…
June 30, 2022

Read more

PharmaShots Interview GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythematosus
VIEWPOINTS

PharmaShots Interview: GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythematosus

In an interview with PharmaShots, Angela Carroll, US Medical Affairs Scientific Director-Immuno-inflammation at GSK shared her views on a first published article on disease modification in systemic lupus erythematosus, published in Lupus Science & MedicineShots:The company has published the first research to define disease modification in SLE including LN in the Lupus Science & Medicine. In multiple therapeutic…
May 11, 2022

Read more

PharmaShots Interview GSK’s Tom Corbridge Shares Insights on Nucala as At-Home Treatment Option for Children with Severe Eosinophilic Asthma
VIEWPOINTS

PharmaShots Interview: GSK’s Tom Corbridge Shares Insights on Nucala as At-Home Treatment Option for Children with Severe Eosinophilic Asthma

In an interview with PharmaShots, Tom Corbridge, Senior Medical Lead at GSK shared his views on the approval of its anti-IL-5 biologic NUCALA (mepolizumab) in a 40 mg pre-filled syringe for appropriate children aged 6 to 11 years old with severe eosinophilic asthma (SEA)Shots:Nucala can now be given by a child’s HCPs or administered…
May 4, 2022

Read more

PharmaShots' Key Highlights of First Quarter 2022
INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2022

The first quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include Biocon acquired Viatris’ biosimilars assets for ~$3.335B, Stryker signed a definitive agreement to acquire Vocera Communications for ~$3.09B, Biohaven acquire Channel Biosciences for ~$3BThe first quarter of the year also showcases regulatory events…
March 31, 2022

Read more

Viewpoints_Tania Small
VIEWPOINTS

PharmaShots Interview: GSK’s Tania Small Shares Insight on Target the Future Program

In an interview with PharmaShots, Tania Small, Vice President of Global Medical Oncology at GSK shares her views on the launch of Target the Future Program to help address the challenges affecting the multiple myeloma communityShots:The company has launched Target the Future program to educate people in the field of multiple myeloma and address unmet needs in the communityA grant of…
February 23, 2022

Read more

Viewpoints_Thomas C. Corbridge
VIEWPOINTS

PharmaShots Interview: GSK’s Thomas C. Corbridge Shares Insights on the New Survey Data for Severe Eosinophilic Asthma Patients

In an interview with PharmaShots, Thomas C. Corbridge, US Senior Medical Lead at GSK shares his views on the new survey and demonstrated dissatisfaction with the asthma treatment paradigmShots:The survey was commissioned by GSK and conducted by The Harris Poll in 100 patients aged ≥18yrs. showed that a majority of SEA patients and physicians are concerned about the current state…
January 18, 2022

Read more

Load more